Structure-activity relationships for serotonin transporter and dopamine receptor selectivity.
Antipsychotic medications have a diverse pharmacology with affinity for serotonergic, dopaminergic, adrenergic, histaminergic and cholinergic receptors. Their clinical use now also includes the treatment of mood disorders, thought to be mediated by serotonergic receptor activity. The aim of our study was to characterise the molecular properties of antipsychotic agents, and to develop a model that would indicate molecular specificity for the dopamine (D(2)) receptor and the serotonin (5-HT) transporter. Back-propagation artificial neural networks (ANNs) were trained on a dataset of 47 ligands categorically assigned antidepressant or antipsychotic utility. The structure of each compound was encoded with 63 calculated molecular descriptors. ANN parameters including hidden neurons and input descriptors were optimised based on sensitivity analyses, with optimum models containing between four and 14 descriptors. Predicted binding preferences were in excellent agreement with clinical antipsychotic or antidepressant utility. Validated models were further tested by use of an external prediction set of five drugs with unknown mechanism of action. The SAR models developed revealed the importance of simple molecular characteristics for differential binding to the D(2) receptor and the 5-HT transporter. These included molecular size and shape, solubility parameters, hydrogen donating potential, electrostatic parameters, stereochemistry and presence of nitrogen. The developed models and techniques employed are expected to be useful in the rational design of future therapeutic agents.
Rural Clinical Division, School of Medicine, The University of Queensland, Toowoomba, QLD, Australia.
Snezana
S
Agatonovic-Kustrin
Paul
P
Davies
Joseph V
JV
Turner
D000927:Anticonvulsants / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000737:chemistry* / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D008968:Molecular Conformation; D019964:Mood Disorders / Q000188:drug therapy; D016571:Neural Networks, Computer; D021281:Quantitative Structure-Activity Relationship; D011954:Receptors, Dopamine / Q000378:metabolism*; D050486:Serotonin Plasma Membrane Transport Proteins / Q000378:metabolism*; D013379:Substrate Specificity
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D008024:Ligands; D011954:Receptors, Dopamine; D050486:Serotonin Plasma Membrane Transport Proteins